Contract drug manufacturing (CDMO) stocks
CDMO
What are Contract drug manufacturing (CDMO) stocks in Korea?
The Contract drug manufacturing (CDMO) theme on jonbur groups 24 Korean stocks listed on KOSPI and KOSDAQ, worth ₩128T in total. On Oct 28, 2026 the group moved up 0.40% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Hanmi Pharm.
Key facts
- Stocks
- 24
- Total market value
- ₩128T
- Day's move
- +0.40%
- As of
- Oct 28, 2026
- Largest members
- Samsung Biologics, Celltrion, Hanmi Pharm
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Celltrion | Oct 12Preliminary | ₩1.5T | +45.8% | ₩510B | +69.2% | +12.9% | 34.0%29.3% |
| Hanmi Pharm | Oct 27Preliminary | ₩377B | +4.2% | ₩38B | −31.3% | −71.2% | 10.0%15.2% |
| ST Pharm | Oct 27Preliminary | ₩98B | +19.1% | ₩16B | +6.6% | −14.3% | 16.1%18.0% |
| Dong-A ST | Oct 27Preliminary | ₩207B | −4.4% | ₩21B | +52.9% | +239.9% | 10.4%6.5% |
| Samsung Biologics | Expected around Oct 28 | ||||||
| SK Bioscience | Expected around Nov 3 | ||||||
| GC Biopharma | Expected around Nov 3 | ||||||
| Chong Kun Dang Pharmaceutical | Expected around Nov 3 | ||||||
| IL Dong Pharmaceutical | Expected around Nov 6 | ||||||
| Daewoong Pharma | Expected around Nov 7 | ||||||
| Huons | Expected around Nov 10 | ||||||
| GL Pharm Tech | Expected around Nov 10 | ||||||
| Aprogen Biologics | Expected around Nov 13 | ||||||
| SAM Chun Dang Pharm | Expected around Nov 14 | ||||||
| Proteina | Expected around Nov 14 | ||||||
| Samyang Holdings | Expected around Nov 14 | ||||||
| Binex | Expected around Nov 14 | ||||||
| BNC Korea | Expected around Nov 14 | ||||||
| Kolon Life Science | Expected around Nov 14 | ||||||
| Prestige Biologics | Expected around Nov 14 | ||||||
| SeouLin Bioscience | Expected around Nov 14 | ||||||
| Prestige BioPharma | Expected around Nov 28 | ||||||
| Inventage Lab | Expected around Dec 1 | ||||||
| BioInfra Life Science | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 28, 2026- Above 20-day average
- 21.7%
- Above 60-day average
- 17.4%
- RSI above 70
- 0%
- RSI below 30
- 17.4%
- 52-week highs
- 0
- 52-week lows
- 4
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The contract drug manufacturing (CDMO) theme covers 23 Korean members, and only 21.7% are trading above their 20-day averages while 17.4% sit above their 60-day averages. No members are showing RSI readings in overbought territory, with the highest reading at 0, while 17.4 is the lowest RSI reading recorded, and four members have touched 52-week lows with none reaching 52-week highs. The equal-weighted member index screens bearish on both short and medium horizons, with 7 bearish signals against no bullish ones, sits below its cloud, and carries an RSI of 35.1.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
- MaturitiesOct 20, 202685SK Reit: ₩130bn of bonds due in the next 6 months vs ₩54bn cash₩350bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2025 FY.SK ReitSK hynixSK NetworksSK DiscoverySKCSK Telecom
Creators talking about this
Contract drug manufacturing (CDMO)
−6.29%CDMO
The CDMO (contract development and manufacturing organization) theme covers Korean companies that develop and manufacture pharmaceuticals, biologics, and related products on behalf of other drug companies, rather than selling their own branded medicines. Korean investors often group these firms together because they share a business model centered on large-scale bioproduction capacity, long-term client contracts, and exposure to the global biopharma outsourcing trend. The theme is also frequently linked to the broader Korean biotech sector, so its share prices tend to move alongside related names.
24 companies · 7 up · 0 flat · 17 down
- Traded value
- ₩267B
- Value vs 20-day average
- 0.80×
- Top gainer
- SAM Chun Dang Pharm +14.67%
- Largest company
- Samsung Biologics ₩64T
Companies in this theme
| Company | Price | Monthly | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
ST Pharm237690 · KOSDAQ | ₩77,200 | −15.44% | ₩29B | ₩1.6T | 5.77% |
Source: KRX statistical information